Adhesive shoulder capsulitis is a condition characterised by stiffness or lack of mobility of the shoulder. This results in a negative impact on quality of life and increased health care costs. Inflammation is a key factor in the pathogenesis of these patients. In addition, poor sleep quality and/or sleep deprivation can increase the production of pro-inflammatory cytokines, which contributes to the development of chronic inflammatory and metabolic diseases. The most important function of sleep is recovery. Good sleep promotes healing, aids in the recovery of the immune, neurological, musculoskeletal systems and is necessary for pain sufferers to improve. The quantity and quality of sleep has an impact on the subject's inflammatory and metabolic markers. In relation to the quantity and quality of sleep, it has been shown that foods and/or beverages rich in methylxanthine such as coffee, tea and chocolate can alter these parameters. As is the case with exposure to blue light emitted by electronic devices. The population are faced with deep-rooted habits in their daily lives that do not help to control pain in these patients. HYPOTHESIS: Due to the above, the following hypothesis is established: Lack of consumption of food or beverages rich in methylxanthine and limiting the use of mobile devices two hours before going to sleep favours recovery from adhesive shoulder capsulitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
34
-Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.
* Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy. * Modification of the biorhythm will consist of eliminating methylxanthine-rich foods and/or beverages from their diet, as well as no exposure to electronic devices two hours before bedtime.
Hospital Reina Sofía de Córdoba
Córdoba, Spain
Pain and Disability Questionnaire (SPADI)
It is a quality of life questionnaire developed to assess pain and disability associated with shoulder dysfunction. The SPADI is a 13-item shoulder function index of responders' ability to perform basic activities of daily living. Each item is scored using a numerical rating scale ranging from zero (no pain/no difficulty) to ten (worst pain imaginable/so difficult that help was required). SPADI provides a pain scale (five items; scale score range from zero to 50 points, expressed as a percentage) and a disability scale (eight items; scale score range from zero to 80 points, expressed as a percentage). The scores of the two scales are averaged to obtain a total Spanish version of the SPADI score (zero to 100 points). A higher score indicates greater pain-related disability.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
Fasting glucose Metabolic Profile
Fasting glucose (mg/dl) was measured. Blood sample was obtained following the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
Insulin Metabolic Profile
Insuline (mU/L) was measured. Blood sample was obtained following the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
HOMA Index Metabolic Profile
HOMA index was measured. Blood sample was obtained following the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
Leptin Metabolic Profile
Leptin (ng/ml) was measured. Blood sample was obtained following the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
Triglycerides Metabolic Profile
Triglycerides (mg/dl) was measured. Blood sample was obtained following the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
Total Colesterol Metabolic Profile
Total colesterol (mg/dl) was measured. Blood sample was obtained following the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
HDL Colesterol Metabolic Profile
HDL colesterol (mg/dl) was measured. Blood sample was obtained following the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
Uric Acid Metabolic Profile
Uric acid (mg/dl) was measured. Blood sample was obtained following the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
High-sensitivity C-reactive Protein Metabolic Profile
High-sensitivity C-reactive Protein (mg/L) was measured. Blood sample was obtained following the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
IL-1 Inflammatory Profile
IL-1 (pg/ml) was measured. The analysis of this inflammatory cytokines was conducted using ELISA (Enzyme-Linked Immunosorbent Assay), with a blood sample obtained according to the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
IL-6 Inflammatory Profile
IL-6 (pg/ml) was measured. The analysis of this inflammatory cytokines was conducted using ELISA (Enzyme-Linked Immunosorbent Assay), with a blood sample obtained according to the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
IL-17 Inflammatory Profile
IL-17 (pg/ml) was measured. The analysis of this inflammatory cytokines was conducted using ELISA (Enzyme-Linked Immunosorbent Assay), with a blood sample obtained according to the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
IL-10 Inflammatory Profile
IL-10 (pg/ml) was measured. The analysis of this inflammatory cytokines was conducted using ELISA (Enzyme-Linked Immunosorbent Assay), with a blood sample obtained according to the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
IL-33 Inflammatory Profile
IL-33 (pg/ml) was measured. The analysis of this inflammatory cytokines was conducted using ELISA (Enzyme-Linked Immunosorbent Assay), with a blood sample obtained according to the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
HMGB1 Inflammatory Profile
HMGB1 (ug/L) was measured. The analysis of this inflammatory cytokines was conducted using ELISA (Enzyme-Linked Immunosorbent Assay), with a blood sample obtained according to the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
CRP Inflammatory Profile
CRP (mg/L) was measured. The analysis of this inflammatory cytokines was conducted using ELISA (Enzyme-Linked Immunosorbent Assay), with a blood sample obtained according to the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
TNF Inflammatory Profile
TNF (pg/ml) was measured. The analysis of this inflammatory cytokines was conducted using ELISA (Enzyme-Linked Immunosorbent Assay), with a blood sample obtained according to the guidelines of the National Biobank Network.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
Pittsburg Sleep Quality Index (PSQI)
It is a questionnaire that assess sleep quality and sleep disturbances. It consists of 19 questions that address a wide variety of factors relating to sleep quality, including estimates of sleep duration and latency and of the frequency and severity of sleep-related problems. The 19 items are grouped into seven component scores, each weighted equally on a 0-3 scale. The component scores are summed to give an overall PSQI score between 0 and 21. A higher scores indicates worse sleep quality.
Time frame: It was measured before starting treatment and at the end of the treatment, an average of 6 months.
Shoulder mobility
Participants' shoulder range of motion will be assessed using an inclinometer. Flexion-extension, abduction-adduction and rotations will be measured.
Time frame: It was measured before starting treatment and at the end of treatment, an average of 6 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.